Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A411WF | ISIN: US73017P2011 | Ticker-Symbol:
NASDAQ
15.05.25 | 17:41
2,390 US-Dollar
-5,16 % -0,130
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PMGC HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
PMGC HOLDINGS INC 5-Tage-Chart

Aktuelle News zur PMGC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q1
MiPMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)1
PMGC Aktie jetzt für 0€ handeln
DiPMGC Holdings Inc. - 8-K, Current Report-
01.05.PMGC Holdings Inc. - 8-K, Current Report1
29.04.PMGC Holdings Inc.: RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health1
29.04.PMGC Holdings Inc.: Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health76NEWPORT BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the "Company," "PMGC," "we," or "our"), today...
► Artikel lesen
28.04.PMGC Holdings Inc.: Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial1
24.04.PMGC Holdings Inc.: Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment80Northstrive Biosciences received preliminary meeting responses from the FDA regarding Northstrive's nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1...
► Artikel lesen
24.04.PMGC Holdings Inc. - 8-K, Current Report-
19.04.Key deals this week: Vista Energy, PMGC Holdings, Colliers, John Wood and more2
16.04.PMGC Holdings to acquire a U.S.-based custom IT packaging company; shares fall5
10.04.PMGC Stock Surges After Subsidiary Inks Deal With Yuva Biosciences To Develop AI Led Therapies2
07.04.PMGC Holdings Inc. - 8-K, Current Report2
07.04.PMGC Holdings Inc. - S-1/A, General form for registration of securities1
28.03.PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K1
27.03.PMGC Holdings Inc.: NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market1
21.03.PMGC Holdings sichert sich 1,48 Millionen US-Dollar durch Direktplatzierung-
21.03.PMGC Holdings secures $1.48 million in direct offering1
21.03.PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules2
21.03.PMGC Holdings Stock Rises 10% Following Share Repurchase1
Seite:  Weiter >>
75 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1